Advertisement
U.S. markets close in 22 minutes

Biophytis S.A. (BPTS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2990-0.0160 (-5.08%)
As of 03:25PM EDT. Market open.
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • ACCESSWIRE

    Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program

    PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related ...

  • ACCESSWIRE

    Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity

    IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized ...

  • Benzinga

    Why Is Penny Stock Biophytis Trading Higher On Tuesday?

    Monday, Biophytis SA (NASDAQ:BPTS) announced the launch of a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity combined with GLP-1 receptor agonists. The OBA Phase 2 clinical study is expected to start in mid-2024, upon regulatory approvals, with the first patients expected to be treated in the second half of 2024. BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs and following hypocaloric dietin